NCT03150160View on ClinicalTrials.gov

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

December 4, 2017

Study Completion Date

December 4, 2017

Conditions
Glaucoma
Interventions
DRUG

brinzolamide 1%/brimonidine 0.2% fixed combination

One drop applied topically to the affected eye(s) in the morning and evening

DRUG

Placebo

One drop applied topically to the affected eye(s) in the morning and evening

DRUG

travoprost 0.004% ophthalmic solution

One drop applied topically to the affected eye(s) in the evening

Trial Locations (1)

03080

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY